Model Informed Drug Development Archives

Publication

再発または難治性の骨髄線維症およびその他の骨髄系・固形腫瘍を対象としたNavtemadlinの集団薬物動態・薬力学解析

This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…

Danielle Pillsbury2025年2月6日

Publication

Understanding Variability in CAR-T Cell Therapy Kinetics

Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…

Danielle Pillsbury2025年1月23日

Publication

Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region

The integration of MID3 offers a transformative opportunity for the MENA region to advance pharmaceutical…

Danielle Pillsbury2025年1月14日

On-Demand Webinar

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…

Danielle Pillsbury2025年1月9日

On-Demand Webinar

From Research to Real-World Impact: A Model Informed Drug Development (MIDD) Framework to Support Understudied Populations

SVP, Client and Regulatory Strategy, Certara Dr. Karen Rowland Yeo is Senior Vice-President, Client &…

Danielle Pillsbury2025年1月3日

Poster

Population Pharmacokinetics (PopPK) of Revumenib in Patients with Relapsed/Refractory Acute Leukemias

Danielle Pillsbury2024年12月12日

Video

Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development

At the 2024 AAPS PharmSci 360 conference, Bioanalysis Zone interviewed Piet van der Graaf, Senior…

Certara2024年12月10日

Publication

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…

Danielle Pillsbury2024年12月9日

Article

Forbes: Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

Published: 2024年11月27日 Recent decades have seen continuing declines in pharmaceutical R&D productivity. Inflation…

Certara2024年11月27日

Poster

Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi

Danielle Pillsbury2024年11月22日

Powered by Translations.com GlobalLink Web Software

モデルに基づく医薬品開発

再発または難治性の骨髄線維症およびその他の骨髄系・固形腫瘍を対象としたNavtemadlinの集団薬物動態・薬力学解析

Understanding Variability in CAR-T Cell Therapy Kinetics

Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

From Research to Real-World Impact: A Model Informed Drug Development (MIDD) Framework to Support Understudied Populations

Population Pharmacokinetics (PopPK) of Revumenib in Patients with Relapsed/Refractory Acute Leukemias

Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

Forbes: Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi

メルマガ登録

クイックアクセス

ソリューション

お問合せ